Alexander G. Allen, et al. EDIT-202, a multiplexed AsCas12a-edited iPSC-differentiated iNK, displays a mature phenotype, high KIR expression, and ADCC towards multiple solid tumor lines. Presented at The Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12, 2022.

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences